GeoVax Labs (NASDAQ: GOVX) plans appeal of Nasdaq delisting
Rhea-AI Filing Summary
GeoVax Labs, Inc. (GOVX) reports that Nasdaq has determined to delist its common stock after the company failed to maintain the $1.00 per share minimum bid price for 30 consecutive business days from July 16 through August 26, 2026, violating Nasdaq Listing Rule 5550(a)(2). Because GeoVax implemented a 1-for-25 reverse stock split on January 12, 2026, it is not eligible for the usual 180‑day cure period. The company had already been notified it did not meet the $2,500,000 stockholders’ equity requirement under Listing Rule 5550(b). Trading is expected to be suspended on September 8, 2026 unless GeoVax timely requests a hearing by September 3, 2026, which it plans to do. The stock will continue trading during the appeal, but there is no assurance of a favorable outcome or that listing compliance will be regained.
Positive
- None.
Negative
- Nasdaq delisting determination due to bid price below $1.00 for 30 consecutive business days, creating risk to the GOVX Nasdaq listing.
- Company is also noncompliant with Nasdaq’s $2,500,000 stockholders’ equity requirement, increasing the hurdles to regaining full listing compliance.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Minimum bid price requirement: $1.00 per share
Period of bid price noncompliance: 30 consecutive business days
Reverse stock split ratio: 1-for-25
+3 more
6 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) minimum bid price for continued listing
Period of bid price noncompliance
30 consecutive business days
From July 16, 2026 through August 26, 2026 closing bid below $1.00
Reverse stock split ratio
1-for-25
Reverse stock split effected on January 12, 2026
Stockholders’ equity requirement
$2,500,000
Nasdaq Listing Rule 5550(b) minimum stockholders’ equity requirement
Expected trading suspension date
September 8, 2026
Date trading is expected to be suspended absent a timely hearing request
Hearing request deadline
September 3, 2026
Deadline set in the Staff Determination Letter to request a hearing
Key Terms
Staff Determination Letter, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A)(iv), Nasdaq Listing Rule 5550(b), +1 more
5 terms
Staff Determination Letter regulatory
"received a Staff Determination Letter (the “Letter”) from the Listing"
A staff determination letter is a written decision from the employees of a government or market regulator about a specific filing, application or compliance question; it tells a company whether the regulator accepts, rejects or needs more information. For investors, it matters because the letter can affect a company’s ability to sell securities, keep a stock listing, or move forward with a product or transaction—similar to a building inspector’s report that decides if construction can continue.
Nasdaq Listing Rule 5550(a)(2) regulatory
"does not comply with Nasdaq Listing Rule 5550(a)(2), which requires"
Nasdaq Listing Rule 5810(c)(3)(A)(iv) regulatory
"under Nasdaq Listing Rule 5810(c)(3)(A)(iv), which applies when an"
Nasdaq Listing Rule 5550(b) regulatory
"not compliant with the minimum $2,500,000 stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)"
A Nasdaq listing rule that requires companies on the Nasdaq Capital Market to keep their share price at or above a minimum level (commonly $1.00 per share) to avoid delisting. It matters to investors because dropping below that threshold can start a formal review that may remove a stock from the exchange, which can reduce trading liquidity, make shares harder to sell, and hurt a company’s ability to raise capital — similar to a store losing its grade and being forced to close or move to a less prominent location.
Nasdaq Hearings Panel regulatory
"request a hearing before the Nasdaq Hearings Panel before the September"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
FAQ
Why did Nasdaq decide to delist GeoVax Labs (GOVX)?
Nasdaq issued a Staff Determination Letter after the closing bid price of GeoVax’s common stock stayed below $1.00 per share for 30 consecutive business days from July 16 through August 26, 2026, causing noncompliance with Nasdaq Listing Rule 5550(a)(2).
How does GeoVax’s prior reverse stock split affect its Nasdaq compliance?
GeoVax effected a 1-for-25 reverse stock split on January 12, 2026. Because this occurred within the prior year, Nasdaq determined the company is not eligible for the customary 180‑day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv).
What other Nasdaq listing rule is GeoVax Labs (GOVX) not meeting?
GeoVax previously disclosed noncompliance with the $2,500,000 stockholders’ equity requirement under Nasdaq Listing Rule 5550(b), in addition to the minimum bid price deficiency described in the Staff Determination Letter.
When could trading in GeoVax Labs (GOVX) be suspended from Nasdaq?
Absent a timely hearing request, Nasdaq states that trading in GeoVax’s securities is expected to be suspended at the opening of business on September 8, 2026, following the Staff’s delisting determination.
What steps is GeoVax Labs (GOVX) taking in response to the Nasdaq delisting notice?
GeoVax plans to timely request a hearing before the Nasdaq Hearings Panel by the September 3, 2026 deadline. A timely request will stay further actions, and the stock will remain listed and trading during the appeal, though there is no assurance of continued listing.
Will GeoVax Labs (GOVX) definitely be delisted from Nasdaq?
No final outcome is stated. GeoVax will appeal to the Nasdaq Hearings Panel, and the stock remains listed during the process. However, the company notes there can be no assurance that continued listing will be granted or that all Nasdaq requirements will be regained.
AI-generated analysis. How Rhea-AI works. Not financial advice.
